Form 4: Innoviva's Chief Accounting Officer, Marianne Zhen, Reports Stock and Option Awards

Marianne Zhen, Chief Accounting Officer of Innoviva, Inc., reports the acquisition of stock and option awards.

Summary

• On March 5, 2024, Marianne Zhen, the Chief Accounting Officer of Innoviva, Inc., reported transactions involving Innoviva's common stock and non-statutory stock options.
• Zhen acquired 10,752 shares of common stock at a price of $14.88 per share.
• She also acquired 23,022 non-statutory stock options with an exercise price of $14.88.
• Following these transactions, Zhen beneficially owns 47,566 shares of common stock and 63,022 derivative securities.
• The stock options vest 25% on February 20, 2025, and the balance in twelve substantially equal installments thereafter on each three-month anniversary of the initial vesting date, subject to continuous service.
• Vesting of the options may accelerate under certain change in control or termination scenarios.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing stock and option grants. It doesn't convey strong positive or negative sentiment, but rather reflects routine compensation practices.

Positives

• The grant of stock and options to a key officer aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the Chief Accounting Officer.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options and RSUs suggests an expectation of continued service from the reporting person.

Industry Context

This filing is a routine disclosure of stock and option awards to a company executive, which is a common practice in publicly traded companies to incentivize and retain key personnel. It doesn't necessarily indicate a specific trend or event within the broader pharmaceutical or biotechnology industry.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of compensation packages for executives in publicly traded companies, including those in the pharmaceutical and biotechnology sectors.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity-based compensation to align executive interests with shareholder value.
• The vesting schedules and terms described in this filing are generally consistent with industry norms for executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock and option grants as a way to align management's interests with the company's long-term success.
• Employees may see this as a positive sign of investment in key personnel.
• The grants have a dilutive effect on existing shareholders, although this is a common and generally accepted practice.

Key Dates